References
- Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231(25):232–5
- Fu JY, Masferrer JL, Siebert K, et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265(28):16737–40
- Hawkey CJ. COX-2 inhibitors. Lancet 1999;353(9149):307–14
- Lipsky LP, Abramson SB, Crofford L, et al. The classification of cyclooxygenase inhibitors. (Editorial) J Rheumatol 1998;25(12): 2298–303
- Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330(18): 1287–94
- Noble S, Balfour JA. Meloxicam. Drugs 1996;51(3):424–32
- Davis R, Brogden RN. Nimesulide: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994;48(3):431–54
- Cipollone F, Ganci A, Panara MR, et al. Effects of nabumetone on prostanoid biosynthesis in humans. Clin Pharmacol Ther 1995;58(3):335–41
- Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998;41(9): 1591–602
- Hubbard R, Geis GS, Woods E, et al. Efficacy, tolerability, and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis. (Abstr) Arthritis Rheum 1998;41(Suppl 9):196S
- Geiss GH, Hubbard RC, Callison DA, et al. Safety and efficacy of celecoxib, a specific COX-2 inhibitor, in osteoarthritis. Rheumatol Eur 1998;27(Suppl 1): 118
- Geiss GH, Stead H, Morant SV, et al. Endoscopic and tolerability results from a study of celecoxib, a specific COX-2 inhibitor, in patients with rheumatoid arthritis. Rheumatol Eur 1998;27(Suppl 1): 118
- Hubbard RC, Mehlisch DR, Jasper DR, et al. SC-58635, a highly selective inhibitor of COX-2, is an effective analgesic in an acute post-surgical pain model. J Invest Med 1996;44(3):293A
- Cannon G, Caldwell J, Holt P, et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial. (Abstr) Arthritis Rheum 1998;41(Suppl 9):196S
- Saag K, Fisher C, McKay J, et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial. (Abstr) Arthritis Rheum 1998;41(Suppl 9):196S
- Ehrich EW, Dallob A, De Lepeleire 1, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999;65(3):336–47
- Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in ApeΔ716 knockout mice by inhibition of cyclooxy- genase 2 (COX-2). Cell 1996;87(5):803–9
- Smalley WE, DuBois RN. Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 1997;39:1–20
- Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of in- domethacin in Alzheimer's disease. Neurology 1993;43(8):1609–11
- Sousa AR, Pfister R, Christie PE, et al. Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax 1997;52(11):940–5
- Sorli CH, Zhang H, Armstrong MB, et al. Basal expression of cyclooxygenase-2 and nuclear factor-interleukin 6 are dominant and coordinately regulated by interleukin 1 in the pancreatic islet. Proc Natl Acad Sci USA 1998;95(4):1788–93
- Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93(5):705–16
- Vainio H, Morgan G. Cyclo-oxygenase-2 and breast cancer prevention: non-steroidal anti-inflammatory agents are worth testing in breast cancer. (Editorial) BMJ 1998;317(Sep 26):828–30
- Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112(2):387–97
- Rossat J, Maillard M, Nussberger J, et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999;66(1):76–84
- Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemody-namica, and eicosanoids. J Pharmacol Exp Ther 1999;289(2):735–41
- Lim H, Paria BC, Das SK, et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997;91 (2): 197–208